Eosinophils play a pivotal role in the inflammatory pathology of asthma and have been the
target of new biologic treatments for patients with eosinophilic asthma. Given the central role …

Background Eosinophilia is associated with worsening asthma severity and decreased lung
function, with increased exacerbation frequency. We assessed the safety and efficacy of …

Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease
phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin …

Background Eosinophilic inflammation is frequently associated with increased asthma
severity. Benralizumab is a humanized, afucosylated, anti–interleukin-5Rα monoclonal …

Objective: Benralizumab, an anti-eosinophilic monoclonal antibody, in combination with
high-dosage inhaled corticosteroids and long-acting β 2-agonists (ICS/LABA), significantly …

Background: Benralizumab, a humanized, anti-interleukin-5 (anti-IL-5) receptor α
monoclonal antibody that directly and rapidly depletes eosinophils, has shown significant …

Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic
asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti …

Background Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α
monoclonal antibody that induces direct, rapid, and nearly complete depletion of …

abstract IL-5 is the most potent activator of eosinophils and is produced by Th2 cells and
ILC2s. A role for IL-5 in eosinophil extracellular trap cell death, ie, a proinflammatory cell …

Introduction: Since the discovery of eosinophils in the sputum of asthmatic patients, several
studies have offered evidence on their prominent role in the pathology and severity of …